Wall Street brokerages expect that CVS Health Corp (NYSE:CVS) will announce sales of $63.03 billion for the current quarter, according to Zacks Investment Research. Twenty Four analysts have issued estimates for CVS Health’s earnings, with the highest sales estimate coming in at $63.95 billion and the lowest estimate coming in at $61.64 billion. CVS Health reported sales of $47.27 billion during the same quarter last year, which would suggest a positive year-over-year growth rate of 33.3%. The business is expected to announce its next quarterly earnings results on Tuesday, November 5th.

On average, analysts expect that CVS Health will report full year sales of $252.36 billion for the current financial year, with estimates ranging from $248.37 billion to $254.27 billion. For the next financial year, analysts expect that the company will post sales of $255.92 billion, with estimates ranging from $240.19 billion to $271.07 billion. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for CVS Health.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, August 7th. The pharmacy operator reported $1.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.70 by $0.19. The business had revenue of $63.43 billion during the quarter, compared to analysts’ expectations of $62.66 billion. CVS Health had a return on equity of 16.15% and a net margin of 1.91%. The firm’s revenue for the quarter was up 35.2% compared to the same quarter last year. During the same period in the previous year, the company posted $1.69 earnings per share.

A number of research firms have recently weighed in on CVS. TheStreet upgraded CVS Health from a “c+” rating to a “b-” rating in a research report on Monday. Evercore ISI set a $63.00 price target on CVS Health and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Morgan Stanley reaffirmed a “buy” rating and issued a $74.00 price target on shares of CVS Health in a research note on Sunday, August 11th. ValuEngine cut shares of CVS Health from a “sell” rating to a “strong sell” rating in a research report on Tuesday, July 2nd. Finally, Citigroup increased their price objective on shares of CVS Health from $68.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. CVS Health has an average rating of “Buy” and a consensus price target of $75.18.

NYSE CVS traded up $0.39 during midday trading on Friday, hitting $63.99. The company had a trading volume of 7,119,461 shares, compared to its average volume of 10,862,482. The company has a market capitalization of $82.82 billion, a PE ratio of 9.04, a P/E/G ratio of 1.39 and a beta of 0.85. The company has a current ratio of 0.95, a quick ratio of 0.64 and a debt-to-equity ratio of 1.39. The firm has a 50-day moving average price of $59.26 and a 200-day moving average price of $55.85. CVS Health has a twelve month low of $51.72 and a twelve month high of $82.15.

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of CVS Health by 1.2% during the second quarter. Vanguard Group Inc. now owns 102,367,899 shares of the pharmacy operator’s stock worth $5,578,027,000 after buying an additional 1,167,143 shares in the last quarter. Northern Trust Corp grew its position in CVS Health by 1.1% during the 2nd quarter. Northern Trust Corp now owns 18,328,099 shares of the pharmacy operator’s stock worth $998,699,000 after acquiring an additional 205,275 shares during the last quarter. Geode Capital Management LLC increased its holdings in CVS Health by 36.2% in the 4th quarter. Geode Capital Management LLC now owns 16,462,292 shares of the pharmacy operator’s stock worth $1,076,697,000 after purchasing an additional 4,376,604 shares in the last quarter. Morgan Stanley increased its holdings in CVS Health by 12.8% in the 2nd quarter. Morgan Stanley now owns 13,765,635 shares of the pharmacy operator’s stock worth $750,088,000 after purchasing an additional 1,560,142 shares in the last quarter. Finally, Nordea Investment Management AB raised its position in CVS Health by 2.8% in the first quarter. Nordea Investment Management AB now owns 12,426,745 shares of the pharmacy operator’s stock valued at $670,172,000 after purchasing an additional 340,315 shares during the last quarter. 76.06% of the stock is owned by hedge funds and other institutional investors.

About CVS Health

CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.

Featured Article: What is an overbought condition?

Get a free copy of the Zacks research report on CVS Health (CVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.